Which has stronger earnings and valuation, BHVN or LNTH?

Lantheus has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A Lantheus $1.55B 4.24 $233.56M $4.15 24.27

Is BHVN or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Biohaven's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Lantheus 18.05% 29.32% 15.00%

Does the media favor BHVN or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Biohaven. Lantheus' average media sentiment score of 0.54 beat Biohaven's score of 0.33 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or BHVN?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Biohaven. Protagonist Therapeutics' average media sentiment score of 0.64 beat Biohaven's score of 0.33 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BHVN or SYRE?

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A Spyre Therapeutics N/A N/A -$155.20M -$2.08 N/A

Is BHVN or SYRE more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Spyre Therapeutics N/A -42.88% -27.76%

Does the media favor BHVN or SYRE?

In the previous week, Spyre Therapeutics had 8 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for Spyre Therapeutics and 3 mentions for Biohaven. Biohaven's average media sentiment score of 0.33 beat Spyre Therapeutics' score of 0.01 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BHVN or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for Biohaven. Mirum Pharmaceuticals' average media sentiment score of 0.37 beat Biohaven's score of 0.33 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PTCT or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. PTC Therapeutics' return on equity of -362.45% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% Biohaven N/A -866.46% -137.99%

Does the media prefer PTCT or BHVN?

In the previous week, PTC Therapeutics had 3 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for PTC Therapeutics and 3 mentions for Biohaven. PTC Therapeutics' average media sentiment score of 1.66 beat Biohaven's score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biohaven 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biohaven (BHVN) Competitors

$11.11 +0.31 (+2.88%)

As of 02:56 PM Eastern

Compare

BHVN vs. LNTH, PTGX, SYRE, MIRM, and PTCT

Should you buy Biohaven stock or one of its competitors? MarketBeat compares Biohaven with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biohaven include Lantheus (LNTH), Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Mirum Pharmaceuticals (MIRM), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does Biohaven compare to Lantheus?

Biohaven (NYSE:BHVN) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, Lantheus had 1 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Biohaven. Lantheus' average media sentiment score of 0.54 beat Biohaven's score of 0.33 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Biohaven's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Lantheus	18.05%	29.32%	15.00%

Lantheus has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Lantheus	$1.55B	4.24	$233.56M	$4.15	24.27

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biohaven presently has a consensus target price of $22.27, indicating a potential upside of 99.58%. Lantheus has a consensus target price of $101.86, indicating a potential upside of 1.14%. Given Biohaven's higher probable upside, equities analysts plainly believe Biohaven is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Biohaven has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market.

Summary

Lantheus beats Biohaven on 11 of the 16 factors compared between the two stocks.

How does Biohaven compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biohaven has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Biohaven	N/A	-866.46%	-137.99%

Protagonist Therapeutics has higher revenue and earnings than Biohaven. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	84.19	-$130.15M	-$1.81	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 3 mentions for Biohaven. Protagonist Therapeutics' average media sentiment score of 0.64 beat Biohaven's score of 0.33 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protagonist Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Protagonist Therapeutics presently has a consensus price target of $115.21, suggesting a potential upside of 18.83%. Biohaven has a consensus price target of $22.27, suggesting a potential upside of 99.58%. Given Biohaven's higher possible upside, analysts plainly believe Biohaven is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71

Summary

Protagonist Therapeutics beats Biohaven on 11 of the 16 factors compared between the two stocks.

How does Biohaven compare to Spyre Therapeutics?

Biohaven (NYSE:BHVN) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Biohaven presently has a consensus target price of $22.27, indicating a potential upside of 99.58%. Spyre Therapeutics has a consensus target price of $91.33, indicating a potential upside of 27.49%. Given Biohaven's higher probable upside, equities analysts clearly believe Biohaven is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spyre Therapeutics' return on equity of -42.88% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Biohaven has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 8 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for Spyre Therapeutics and 3 mentions for Biohaven. Biohaven's average media sentiment score of 0.33 beat Spyre Therapeutics' score of 0.01 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A

Summary

Spyre Therapeutics beats Biohaven on 9 of the 13 factors compared between the two stocks.

How does Biohaven compare to Mirum Pharmaceuticals?

Biohaven (NYSE:BHVN) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Biohaven has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Biohaven. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Mirum Pharmaceuticals	$569.61M	9.91	-$23.36M	-$13.61	N/A

Biohaven currently has a consensus target price of $22.27, indicating a potential upside of 99.58%. Mirum Pharmaceuticals has a consensus target price of $137.64, indicating a potential upside of 48.69%. Given Biohaven's higher probable upside, research analysts plainly believe Biohaven is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

88.8% of Biohaven shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biohaven has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for Biohaven. Mirum Pharmaceuticals' average media sentiment score of 0.37 beat Biohaven's score of 0.33 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Biohaven and Mirum Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Biohaven compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Biohaven has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. PTC Therapeutics' return on equity of -362.45% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Biohaven	N/A	-866.46%	-137.99%

88.8% of Biohaven shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PTC Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

PTC Therapeutics presently has a consensus price target of $89.00, indicating a potential upside of 27.48%. Biohaven has a consensus price target of $22.27, indicating a potential upside of 99.58%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71

PTC Therapeutics has higher revenue and earnings than Biohaven. PTC Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.35	$682.64M	-$2.33	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

In the previous week, PTC Therapeutics had 3 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for PTC Therapeutics and 3 mentions for Biohaven. PTC Therapeutics' average media sentiment score of 1.66 beat Biohaven's score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Biohaven beats PTC Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.69B	$3.30B	$6.45B	$23.05B
Dividend Yield	N/A	2.31%	2.67%	4.08%
P/E Ratio	-1.98	19.15	23.92	30.41
Price / Sales	N/A	176.25	480.90	96.46
Price / Cash	N/A	51.45	26.99	18.46
Price / Book	28.61	8.03	10.36	4.63
Net Income	-$738.82M	$23.89M	$3.57B	$1.07B
7 Day Performance	-2.80%	-5.75%	-1.11%	-1.52%
1 Month Performance	13.52%	2.11%	3.40%	-0.92%
1 Year Performance	-34.33%	36.67%	23.87%	21.69%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	2.6763 of 5 stars	$11.11 +2.9%	$22.27 +100.4%	-36.2%	$1.67B	N/A	N/A	239
LNTH Lantheus	2.1715 of 5 stars	$97.13 -2.2%	$101.86 +4.9%	+23.8%	$6.47B	$1.55B	23.40	1,193
PTGX Protagonist Therapeutics	2.4663 of 5 stars	$94.92 -4.7%	$115.21 +21.4%	+79.1%	$6.40B	$46.02M	N/A	120	Gap Up
SYRE Spyre Therapeutics	2.4883 of 5 stars	$70.54 -4.0%	$90.25 +27.9%	+334.0%	$6.38B	$890K	N/A	73	Gap Up
MIRM Mirum Pharmaceuticals	3.3751 of 5 stars	$96.33 -5.1%	$137.08 +42.3%	+101.6%	$6.19B	$521.31M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors

BHVN vs. LNTH, PTGX, SYRE, MIRM, and PTCT

How does Biohaven compare to Lantheus?

Summary

How does Biohaven compare to Protagonist Therapeutics?

Summary

How does Biohaven compare to Spyre Therapeutics?

Summary

How does Biohaven compare to Mirum Pharmaceuticals?

Summary

How does Biohaven compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biohaven (BHVN) Competitors

BHVN vs. LNTH, PTGX, SYRE, MIRM, and PTCT

How does Biohaven compare to Lantheus?

Does the media favor BHVN or LNTH?

Is BHVN or LNTH more profitable?

Which has stronger earnings and valuation, BHVN or LNTH?

Do insiders and institutionals believe in BHVN or LNTH?

Do analysts recommend BHVN or LNTH?

Which has more risk & volatility, BHVN or LNTH?

Summary

How does Biohaven compare to Protagonist Therapeutics?

Do insiders & institutionals hold more shares of PTGX or BHVN?

Is PTGX or BHVN more profitable?

Which has preferable valuation and earnings, PTGX or BHVN?

Does the media prefer PTGX or BHVN?

Which has more volatility & risk, PTGX or BHVN?

Do analysts prefer PTGX or BHVN?

Summary

How does Biohaven compare to Spyre Therapeutics?

Do analysts recommend BHVN or SYRE?

Is BHVN or SYRE more profitable?

Which has more risk & volatility, BHVN or SYRE?

Does the media favor BHVN or SYRE?

Do institutionals and insiders have more ownership in BHVN or SYRE?

Which has stronger earnings & valuation, BHVN or SYRE?

Summary

How does Biohaven compare to Mirum Pharmaceuticals?

Which has more risk and volatility, BHVN or MIRM?

Which has higher valuation & earnings, BHVN or MIRM?

Do analysts rate BHVN or MIRM?

Do insiders and institutionals have more ownership in BHVN or MIRM?

Is BHVN or MIRM more profitable?

Does the media favor BHVN or MIRM?

Summary

How does Biohaven compare to PTC Therapeutics?

Is PTCT or BHVN more profitable?

Do institutionals and insiders have more ownership in PTCT or BHVN?

Which has more risk & volatility, PTCT or BHVN?

Do analysts recommend PTCT or BHVN?

Which has higher valuation & earnings, PTCT or BHVN?

Does the media prefer PTCT or BHVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools